The financing will support clinical trials, product development and team expansion as the business pursues international regulatory approvals.
"Our work in the US and the success of the trials we have run to date have demonstrated the potential of our technology and encouraged us to pursue other applications. With this financing and the backing of our investors we can accelerate our mission of delivering effective and non-invasive solutions for some of the most common and debilitating medical conditions."
Par Equity led the Series A round to support technology development and commercial expansion.
"We are delighted to continue working with Par Equity who have been very supportive of our company and our vision. This investment will enable us to continue to develop and commercialise our cutting-edge technology that addresses a major unmet need in the development of novel therapies that can significantly reduce costs of care and improve patient outcomes for millions of people worldwide."
The London-based digital branding platform secured £2m from Notion Capital, Angel CoFund, and VentureFounders.
"Many years ago we set out to build a platform that would empower programmatic digital trading with levels of creativity not otherwise seen, while baking in as automated features, optimum solutions for real-time fraud management. It has taken a long time but we are truly excited to now be in market with what many say is a game-changing offering. Being able to close a round at this particular time is a testament to that technology offering and the belief shown by existing and new investors alike. I am also thrilled to welcome the Angel CoFund to the business."
The London based data technology start up secured backing from the Angel CoFund to advance its artificial intelligence platform.
"DPL’s unique platform has the ability to transform marketing and customer engagement for countless businesses, and offers a considerably enhanced experience for end consumers. We are very pleased to be supporting a highly experienced team bringing a truly game changing product to market with this funding round, and look forward seeing clients really tangibly benefit from the team’s insights."
The biotechnology spin-out raised funds from backers including the Angel CoFund and o2h Ventures alongside Department of Health and Social Care grants.
"This latest funding further validates our computational design-led focus that has enabled rapid progress in building our pipeline of novel antibiotic programmes."
